Investors Face September Deadline in PROCEPT BioRobotics Class Action

The complaint alleges that PROCEPT incentivized customers to place orders exceeding actual clinical demand, creating a significant glut of field inventory. By the end of the class period, this practice reportedly resulted in more than 10,000 excess handpiece units. These aggressive sales tactics allegedly allowed the company to pull forward future revenue, masking weaker underlying demand for its systems.

Market confidence eroded as the company repeatedly adjusted its financial guidance. Following the February 25, 2026, disclosure regarding the actual number of procedures performed versus unit shipments, PROCEPT stock dropped more than 18% over two trading days. The price continued to slide, falling below $18 per share by late July. Robbins LLP, representing the investors, claims that the company’s failure to disclose these operational risks left shareholders vulnerable to inflated asset values. Investors seeking to participate in the litigation or those requiring further information may contact the firm to discuss their potential legal standing.